Search results
Prediction: These 2 Growth Stocks Could Triple By 2030
Motley Fool via Yahoo Finance· 4 days agoHowever, Axsome's innovative days aren't behind it, which may allow the company to continue...
The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy?
InvestorPlace· 6 days agoWhispers and rumors of widespread cannabis legalization are growing louder. Although the last major...
RFK Jr. Explains Why His Voice Sounds Hoarse
MedPage Today· 6 days agoWelcome to Culture Clinic, MedPage Today's collaboration with Northwell Health to offer a healthcare professional's take on the latest viral medical...
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
InvestorPlace· 4 days agoThe biotech sector holds some of the most promising and popular stocks on the market. With the...
Ventral subiculum promotes wakefulness through several pathways in male mice -...
Nature· 4 days agoThe ventral subiculum (vSUB), the major output structure of the hippocampal formation, regulates motivation, stress integration, and anxiety-like behaviors that rely on heightened arousal. However ...
Prediction: These 2 Growth Stocks Could Triple By 2030 | The Motley Fool
The Motley Fool· 4 days agoDoing so requires a compound annual growth rate of 20.1%, well above the broader market's historical...
Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval
Bloomberg Law· 6 days ago...district court that the FDA violated an orphan drug law when it approved a rival product. will take to the US District Court for the District of Columbia to argue its case against the Food and Drug Administration on whether the agency violated the Orphan Drug Act when it approved Avadel CNS...
Japan's Takeda Pharma to restructure after annual profit slump
Reuters· 6 days ago, opens new tab announced a restructuring on Thursday after annual profit slid by more than half...
Groundbreaking Data Collection Platform Opens to A | Newswise
Newswise· 1 day agoWEST PALM BEACH, Fla., May 14, 2024 /PRNewswire/ -- Sleep Consortium, in partnership with leading sleep-related patient advocacy organizations, the global patient community, and key industry ...
Citigroup Lowers Axsome Therapeutics (NASDAQ:AXSM) Price Target to $125.00
ETF DAILY NEWS· 6 days agoAxsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective reduced by Citigroup from $127.00 to $125.00 in a research note issued to investors on Tuesday, Benzinga reports.
